Adrenal rather than central dysfunction limits hypothalamic–pituitary–adrenal axis recovery after chronic glucocorticoid treatment in male mice
- 8 July 2026
- journal article
- Published by The Endocrine Society in Endocrinology
- Vol. 167 (8)
Abstract
Glucocorticoid-induced adrenal insufficiency (GIAI) can persist for months after discontinuation of chronic corticosteroid therapy, placing patients at risk for life-threatening adrenal crises. This prolonged suppression has been attributed primarily to delayed restoration of hypothalamic–pituitary signaling based on indirect measures of central axis activity. To identify the rate-limiting site of hypothalamic–pituitary–adrenal (HPA) axis recovery, we evaluated the timing of functional and histologic recovery at each node of the axis following 8 weeks of dexamethasone (DEX) treatment in adult, male mice. Dexamethasone administration fully suppressed HPA axis activity. Unexpectedly, within 1 week of DEX withdrawal, hypothalamic Crh mRNA and plasma adrenocorticotropic hormone (ACTH) rebounded above control levels, whereas corticosterone (CORT) remained suppressed for an additional 7 weeks. Dexamethasone-treated adrenals were markedly atrophic and contained large clusters of lipid-filled macrophages. Even after adjusting for macrophage content, CORT secretion was disproportionately low relative to the remaining adrenocortical cell mass despite supraphysiologic ACTH stimulation. The adrenal is thus the principal site of postwithdrawal GIAI, involving adrenocortical cell loss and a superimposed defect in steroidogenesis. We next tested whether preserving adrenal trophic signaling during glucocorticoid exposure could prevent GIAI. Adrenal function recovered more slowly in mice treated with DEX and daily cosyntropin (a synthetic ACTH analog) compared to those treated with DEX alone. In contrast, mice with nonsuppressible endogenous ACTH due to targeted hypothalamic deletion of the glucocorticoid receptor maintained normal adrenal architecture and steroidogenic capacity despite prolonged DEX treatment. Pharmacologic treatments that mimic sustained trophic signaling to the adrenal during chronic glucocorticoid treatment may thus prevent GIAI.Keywords
Funding Information
- Norges Idrettshøgskole (5T32DK007699-39)
- Norges Idrettshøgskole (F32DK131795-02)
- Norges Idrettshøgskole (1K08DK142004-01A1)
- Pediatric Endocrine Society
- Boston Children's Hospital
- Harvard Medical School
This publication has 77 references indexed in Scilit:
- Macrophage regulation of hypothalamic-pituitary-adrenal and gonadal axis homeostasis and hormonal outputBiomedical Journal, 2025
- Prolonged treatment with the synthetic glucocorticoid methylprednisolone affects adrenal steroidogenic function and response to inflammatory stress in the ratBrain, Behavior, and Immunity, 2020
- Factors predicting the duration of adrenal insufficiency in patients successfully treated for Cushing disease and nonmalignant primary adrenal Cushing syndromeEndocrine, 2016
- Adrenocortical Development, Maintenance, and Disease2013
- Prevalence of oral glucocorticoid usage in the United States: A general population perspectiveArthritis Care & Research, 2012
- Steroidogenic acute regulatory protein (StAR), a novel mitochondrial cholesterol transporterBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Corticosteroids2005
- Macrophages within the human adrenal glandCell and tissue research, 1994
- ACTH induces up-regulation of ACTH receptor mRNA in mouse and human adrenocortical cell linesMolecular and Cellular Endocrinology, 1994
- Adrenocortical cell deletion: The role of ACTHThe Journal of Pathology, 1973